A Score to Predict the Clinical Usefulness of Therapeutic Drug Monitoring: Application to Oral Molecular Targeted Therapies in Cancer.
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
23 Feb 2024
23 Feb 2024
Historique:
received:
22
09
2023
accepted:
22
01
2024
medline:
23
2
2024
pubmed:
23
2
2024
entrez:
23
2
2024
Statut:
aheadofprint
Résumé
Therapeutic drug monitoring (TDM) involves measuring and interpreting drug concentrations in biological fluids to adjust drug dosages. In onco-hematology, TDM guidelines for oral molecular targeted therapies (oMTTs) are varied. This study evaluates a quantitative approach with a score to predict the clinical usefulness of TDM for oMTTs. We identified key parameters for an oMTT's suitability for TDM from standard TDM recommendations. We gathered oMTT pharmacological data, which covered exposure variability (considering pharmacokinetic (PK) impact of food and proton pump inhibitors), technical intricacy (PK linearity and active metabolites), efficacy (exposure-response relationship), and safety (maximum tolerated dose, and exposure-safety relationship). To assess the validity and the relevance of the score and define relevant thresholds, we evaluated molecules with prospective validation or strong recommendations for TDM, both in oncology and in other fields. By September 1, 2021, the US Food and Drug Administration (FDA) approved 67 oMTTs for onco-hematological indications. Scores ranged from 15 (acalabrutinib) to 80 (sunitinib) with an average of 48.3 and a standard deviation of 15.6. Top scorers included sunitinib, sorafenib, cabozantinib, nilotinib, and abemaciclib. Based on scores, drugs were categorized into low (< 40), intermediate (≥ 40 and < 60), and high (≥ 60) relevance for TDM. Notably, negative controls generally scored around or under 40, whereas positive controls had a high score across different indications. In this work, we propose a quantitative and reproducible score to compare the potential usefulness of TDM for oMTTs. Future guidelines should prioritize the TDM for molecules with the highest score.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. Clinical Pharmacology & Therapeutics © 2024 American Society for Clinical Pharmacology and Therapeutics.
Références
Cohen, P., Cross, D. & Jänne, P.A. Kinase drug discovery 20 years after imatinib: progress and future directions. Nat. Rev. Drug Discov. 20, 551-569 (2021).
Gougis, P. et al. Major pitfalls of protein kinase inhibitors prescription: a review of their clinical pharmacology for daily use. Crit. Rev. Oncol. Hematol. 141, 112-124 (2019).
de Jonge, M.E., Huitema, A.D.R., Schellens, J.H.M., Rodenhuis, S. & Beijnen, J.H. Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review. Clin. Pharmacokinet. 44, 147-173 (2005).
Ashbee, H.R., Barnes, R.A., Johnson, E.M., Richardson, M.D., Gorton, R. & Hope, W.W. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J. Antimicrob. Chemother. 69, 1162-1176 (2014).
Bouchet, S. & Molimard, M. Pharmacokinetics and therapeutic drug monitoring of anticancer protein/kinase inhibitors. Therapie 77, 157-170 (2022).
Schoretsanitis, G. et al. Blood levels to optimize antipsychotic treatment in clinical practice: A joint consensus statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. J. Clin. Psychiatry 81, 19cs13169 (2020).
Udomkarnjananun, S. et al. Therapeutic drug monitoring of immunosuppressive drugs in hepatology and gastroenterology. Best Pract. Res. Clin. Gastroenterol. 54-55, 101756 (2021).
Widmer, N. et al. Review of therapeutic drug monitoring of anticancer drugs part two - targeted therapies. Eur. J. Cancer 50, 2020-2036 (2014).
Groenland, S.L., Mathijssen, R.H.J., Beijnen, J.H., Huitema, A.D.R. & Steeghs, N. Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine. Eur. J. Clin. Pharmacol. 75, 1309-1318 (2019).
Westerdijk, K., Desar, I.M.E., Steeghs, N., van der Graaf, W.T.A., van Erp, N.P. & on behalf of the Dutch Pharmacology and Oncology Group (DPOG). Imatinib, sunitinib and pazopanib: from flat-fixed dosing towards a pharmacokinetically guided personalized dose. Br. J. Clin. Pharmacol. 86, 258-273 (2020).
Mueller-Schoell, A. et al. Therapeutic drug monitoring of oral targeted antineoplastic drugs. Eur. J. Clin. Pharmacol. 77, 441-464 (2021).
Yu, H., Steeghs, N., Nijenhuis, C.M., Schellens, J.H.M., Beijnen, J.H. & Huitema, A.D.R. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clin. Pharmacokinet. 53, 305-325 (2014).
Verheijen, R.B., Yu, H., Schellens, J.H.M., Beijnen, J.H., Steeghs, N. & Huitema, A.D.R. Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology. Clin. Pharmacol. Ther. 102, 765-776 (2017).
Drugs@FDA: FDA-Approved Drugs <https://www.accessdata.fda.gov/scripts/cder/daf/> Accessed February 3, 2020.
Research C for DE and Center for Drug Evaluation and Research | CDER. FDA <https://www.fda.gov/about-fda/fda-organization/center-drug-evaluation-and-research-cder> (2022). Accessed January 6, 2023.
van der Kleij, M.B.A. et al. Therapeutic drug monitoring of kinase inhibitors in oncology. Clin. Pharmacokinet. 62, 1333-1364 (2023).
Bardin, C. et al. Therapeutic drug monitoring in cancer - are we missing a trick? Eur. J. Cancer 50, 2005-2009 (2014).
Carton, E. et al. Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients. Eur. J. Cancer 72, 54-61 (2017).
van Nuland, M. et al. Exposure-response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 23, 244-251 (2020).
Alexandre, J. et al. Intra-individual dose escalation of abiraterone (ABI) according to its plasma exposure in patients (pts) with progressive metastatic castration-resistant prostate cancer (mRCPC): results of the OPTIMABI trial. J. Clin. Oncol. 41(6_suppl), 159 (2023).
Lankheet, N.A.G., Knapen, L.M., Schellens, J.H.M., Beijnen, J.H., Steeghs, N. & Huitema, A.D.R. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care. Ther. Drug Monit. 36, 326-334 (2014).
Morcos, P.N. et al. Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer. Cancer Chemother. Pharmacol. 82, 129-138 (2018).
Gadgeel, S.M. et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 15, 1119-1128 (2014).
Hong, D.S. et al. KRASG12C inhibition with sotorasib in advanced solid tumors. N. Engl. J. Med. 383, 1207-1217 (2020).
Johnson-Ansah, H. et al. Imatinib optimized therapy improves major molecular response rates in patients with chronic myeloid leukemia. Pharmaceutics 14, 1676 (2022).
Widmer, N. et al. Imatinib plasma levels: correlation with clinical benefit in GIST patients. Br. J. Cancer 102, 1198-1199 (2010).
Rini, B.I. et al. Characterization and management of treatment-emergent hepatic toxicity in patients with advanced renal cell carcinoma receiving first-line pembrolizumab plus axitinib. Results from the KEYNOTE-426 trial. Eur. Urol. Oncol 5, 225-234 (2022).
FDA. Label FDA INLYTA - axitinib <https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202324Orig1s014CorrectedLbl.pdf> (2022). Accessed November 8, 2023.
Weinstein, A. et al. Understanding and managing immune-related adverse events associated with immune checkpoint inhibitors in patients with advanced melanoma. J. Adv. Pract. Oncol. 8, 58-72 (2017).